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Abstract 
Background: The European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire 
for non-muscle invasive bladder cancer (QLQ-NMIBC24) has been available and applied for some years now, but has 
yet to undergo a full comprehensive psychometric evaluation. The aim of this study was to investigate the psycho-
metric properties of the Dutch version of the EORTC QLQ-NMIBC24 questionnaire in patients with low, intermediate 
and high risk NMIBC.
Methods: We included patients newly diagnosed with NMIBC participating in the multicenter, population-based 
prospective cohort studies UroLife or BlaZIB. Psychometric evaluation included examination of the structural valid-
ity, reliability (i.e. internal consistency and test–retest reliability), construct validity (i.e. divergent validity and known-
groups validity), responsiveness and interpretability.
Results: A total of 1463 patients who completed the baseline questionnaire of UroLife (n = 541, response rate 50%) 
or BlaZIB (n = 922, response rate 58%) were included. The percentage of missing responses were low for all non-
sex related scales (< 1%) and ranged between 6.9% to 50.0% for sex-related scales. More than 15% of the patients 
obtained the lowest possible scores on nearly each scale (floor effect). The structural validity was adequate; the 
confirmatory factor analysis showed satisfactory results and all items of multiple items scales had higher within- than 
between-scale correlations. Reliability of the questionnaire was adequate for most multiple item scales (Cronbach’s 
α ≥ 0.70 and intraclass correlation coefficient ≥ 0.70), with exception of the scales ‘malaise’ and ‘bloating and flatu-
lence’. The questionnaire also showed good construct validity; it showed low correlations with the items of the EORTC 
core questionnaire and was able to measure differences between risk-based subgroups. The responsiveness of the 
questionnaire was good, but the interpretability, i.e. minimal important change, could not be determined.
Conclusions: This study shows that the measurement properties of the EORTC QLQL-NMIBC24 are good; it has a 
good structural validity, reliability (i.e. internal consistency and test–retest reliability), construct validity (i.e. divergent 
validity and known-group validity), and responsiveness. Interpretability could not be assessed. This questionnaire can 
be used to measure and monitor health-related quality of life of patients with NMIBC.
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Background
The majority (75%) of new bladder cancer patients 
are diagnosed with non-muscle invasive bladder can-
cer (NMIBC) and undergo a transurethral resection 
(TURBT) [1]. Dependent on the tumour’s risk profile, 
this is followed by a single chemotherapy instillation 
(low-risk tumours), adjuvant intravesical chemotherapy 
or Bacillus Calmette Guerin (BCG) for a maximum of 
1 year (intermediate-risk tumours), or BCG maintenance 
for 1–3 years (high-risk tumours) [1]. As both the disease 
and its treatment can affect functional health and symp-
tom experience, the European Organisation for Research 
and Treatment of Cancer (EORTC) developed a health-
related quality of life (HRQoL) questionnaire specifically 
for patients with NMIBC, the EORTC Quality of Life 
Questionnaire (QLQ)-NMIBC24 [2, 3]. This question-
naire module was designed to complement the EORTC 
core HRQoL questionnaire, the QLQ-C30. The QLQ-
NMIBC24 is already partially validated (i.e. content valid-
ity) but still needs to undergo psychometric testing in a 
large international group of patients (phase III validated 
EORTC module) [4]. To date, three studies have investi-
gated the psychometric properties of the QLQ-NMIBC24 
questionnaire showing its psychometric robustness [2, 
5, 6]. One study examined and revised the scale struc-
ture and evaluated the internal consistency, known 
group validity, and responsiveness of the questionnaire 
in a British patient population [2]. The other two stud-
ies evaluated the psychometric properties of the Danish 
and Korean translation of the questionnaire, respectively 
[5, 6]. However, no full comprehensive evaluation of the 
psychometric properties of the QLQ-NMIBC24, which is 
required to judge the appropriateness of the measure, has 
been performed. Test–retest reliability, interpretability of 
change scores [7] and the performance of the NMIBC24 
has not yet been evaluated in different risk groups of 
NMIBC patients or among Dutch-speaking patients.
Therefore, the aim of this study was to examine the 
structural validity, reliability (i.e. internal consistency 
and test–retest reliability), construct validity (i.e. diver-
gent validity and known group validity), responsiveness 
and interpretability of the Dutch version of the QLQ-




Dutch bladder cancer patients participating in the 
UroLife (Urothelial cell cancer: Lifestyle, prognosis and 
quality of Life) or BlaZIB (‘BlaaskankerZorg In Beeld’, 
clinical trial number: NL8106) studies were included in 
the current analysis. Both studies are population-based, 
multicenter prospective cohort studies recruiting newly 
diagnosed bladder cancer patients based on notifications 
from the nationwide network and registry of histopathol-
ogy and cytopathology in the Netherlands (PALGA) and 
successive registration in the Netherlands Cancer Regis-
try (NCR). The main aim of the Urolife study is to evalu-
ate the association between lifestyle habits and the risk of 
recurrence and progression and HRQoL of patients with 
NMIBC. BlaZIB aims to gain insight in bladder cancer 
care and to identify barriers and modulators for optimal 
care. More detailed information on these studies can be 
found elsewhere [8, 9]. For this analysis, patients diag-
nosed with NMIBC (stage Ta, T1, Tis) between April 1, 
2014 and March 18, 2016 were selected from the UroLife 
study, and patients diagnosed with high-risk NMIBC 
(stage T1 and Tis) between November 1, 2017 and July 
7, 2019 were selected from the BlaZIB study. All patients 
were Dutch speaking, between 18 and 80 years old, and 
treated with a transurethral resection. This study was 
performed in line with the principles of the Declaration 
of Helsinki. The Committee for Human Research in the 
region Arnhem-Nijmegen provided ethical approval 
for the UroLife study (CMO 2013-494) and deemed the 
BlaZIB study exempt from ethical review under the Med-
ical Research Involving Human Subjects Act (WMO). 
Both studies were approved by the ethical review board 
of the NCR. Written informed consent was obtained 
from all patients participating in UroLife or BlaZIB.
Data collection
Both studies collected self-reported questionnaire data 
online or on paper 6 weeks after diagnosis (T6wk). The 
online questionnaires were collected via the data collec-
tion tool of the Patient Reported Outcomes Following 
Initial treatment and Long term Evaluation of Survivor-
ship (PROFILES) registry [10]. Baseline data (T6wk) 
and follow-up data collected at 3  months (T3mo) and 
15 months (T15mo) after diagnosis in the UroLife study, 
and at 6  months (T6mo) and 12  months (T12mo) after 
diagnosis in the BlaZIB study were used for the current 
analysis. The measurement points of UroLife were based 
on the treatment regimen of patients diagnosed with 
NMIBC, i.e. shortly after histological confirmation of 
the tumour (T6wk), at time of cystoscopy to investigate 
whether the tumour was successfully removed (T3mo), 
and long-term follow-up (T15mo). For the BlaZIB study, 
Keywords: Bladder cancer, Quality of life, Validation studies, EORTC questionnaire
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including also patients with Muscle Invasive Bladder 
Cancer, different measurement points were selected. 
Because of the nonconforming measurement points, 
most analyses were based on UroLife data and only sup-
plemented with BlaZIB data where necessary (i.e. test–
retest, interpretability of change scores; see also Fig.  1). 
The baseline questionnaires assessed demographics, 
smoking history, and comorbidity. HRQoL was assessed 
at T6wk and during follow-up using the EORTC-QLQ-
C30 and the QLQ-NMIBC24 questionnaires [2, 11]. 
Patients who underwent a cystectomy were not or no 
longer invited to participate in the UroLife study.
In order to assess the test–retest reliability and 
standard error of measurement (SEM), patients who 
completed the BlaZIB T12mo questionnaire between 
March 1st 2019 and December 7th 2019 received an addi-
tional questionnaire 2 weeks after the T12mo question-
naire (T12mo + 2wk). In total, 134 patients diagnosed 
with NMIBC completed the T12mo + 2wk questionnaire 
(response rate 86.5%). This questionnaire included the 
QLQ-NMIBC24 and four additional questions to assess 
whether the symptoms – in terms of urinary, bowel, 
sexual and total function – had decreased, remained the 
same or increased compared to the T12mo questionnaire 
(three-point Likert scale, see Additional file  1: Appen-
dix A). Patients whose symptoms remained the same 
were regarded as stable and included in the test–retest 
analysis.
1,463 patients eligible for this study
BlaZIB UroLife
922 patients with NMIBC, complete 
questionnaire data (response rate: 
58%ᵃ) and clinical data at baseline 
(T6wk) Table 1
541 patients with complete 
questionnaire data (response rate: 
50%ᵃ) and clinical data at baseline 
(T6wk) Table 1-4,6-8
471 patients with complete 
questionnaire data three months 
after diagnosis (T3mo; response 
rate 87%ᵇ) Table 2,4,8
423 patients with complete 
questionnaire data fifteen months 
after diagnosis (T15mo; response 
rate 90%ᵇ) Table 2,4,8
674 patients with complete 
questionnaire data six months after 
diagnosis (T6mo; response rate 
77%ᵃ)
491 patients with complete 
questionnaire data twelve months 
after diagnosis (T12mo; response 
rate: 66%ᵃ)
134 patients with complete 
questionnaire data for the extra 
questionnaire two weeks after the 
T12 questionnaire (T12mo+2wk; 
response rate: 86%ᵃ) Table 5
Fig. 1 Flowchart BlaZIB and Urolife. NMIBC non-muscle invasive bladder cancer. aPercentage of patients that completed the questionnaire after 
being invited to fill in the questionnaire. bPercentage of patients that completed the questionnaire after completing the previous questionnaire
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In order to assess the minimal important change (MIC), 
the follow-up questionnaires of BlaZIB (T6mo, T12mo) 
contained an anchor question to assess changes over 
time., i.e. ‘Did your bladder cancer-specific complaints 
(urinary, bowel, sexual function and overall) change com-
pared to your complaints at diagnosis?’. Patients were 
asked to score their change on a nine-point Likert scale 
ranging from 1 (worse than ever) to 9 (no complaints 
anymore) for urinary, bowel, sexual and total function, 
separately [12]. We clustered the answers into three cat-
egories: importantly deteriorated (1–3), not importantly 
changed (4–6) and importantly improved (7–9) [13].
HRQoL questionnaires
The EORTC QLQ-C30 is the core HRQoL question-
naire of the EORTC and measures the HRQoL of cancer 
patients. The questionnaire consists of 30 items organ-
ized into a global health status scale, five functioning 
scales (physical, role, cognitive, emotional, and social), 
three symptom scales (fatigue, pain, and nausea and 
vomiting) and six single items (dyspnoea, insomnia, loss 
of appetite, constipation, diarrhea, and financial impact) 
[11].
The QLQ-NMIBC24 is an EORTC module for patients 
diagnosed with NMIBC and should be administered 
in addition to the core questionnaire (EORTC-QLQ-
C30) [4]. The module includes constructs specific to the 
tumour site and treatment of NMIBC. The QLQ-NMIBC 
consists of 24 items organized into six scales (urinary 
symptoms, malaise, future worries, bloating and flatu-
lence, sexual functioning, and male sexual problems) and 
five single items (intravesical treatment issues, sexual 
intimacy, risk of contaminating partner, sexual enjoy-
ment, female sexual problems) [3].
All items were scored on a four-point Likert scale rang-
ing from 1 (not at all) to 4 (very much), with the excep-
tion of the global health status items, which employ a 
seven-point scale ranging from 1 (very poor) to 7 (excel-
lent). Scores of items were summed and linearly trans-
formed to 0–100 scales and missing data were imputed 
according to the EORTC guideline [14]. Higher scores 
on functioning scales and global health status represent 
better functioning, while higher scores on the symptom 
scales indicate more symptom burden. Higher scores on 
the scales and items of the QLQ-NMIBC24 should be 
interpreted as more symptom burden, with exception of 
the sexual function scale and sexual enjoyment where 
higher scores represent better functioning.
Statistical analysis
Floor and ceiling effects were examined for each scale at 
each assessment point. If more than 15% of the patients 
scored at the lowest or highest end of the scale, the scale 
was considered to have a floor or ceiling effect, respec-
tively [15]. Multitrait scaling analysis and Confirmatory 
factor analysis (CFA) were performed to validate the 
constructs of the QLQ-NMIBC24. Convergent validity 
was defined as a correlation of 0.40 or greater between 
an item and its own scale. Discriminant validity was 
defined a as correlation of less than 0.40 between an item 
and any other scale [2, 16]. Maximum Likelihood (ML) 
was used as estimator in the CFA and missing items 
were imputed using Full Info Max Likelihood (fiml). 
Model-data-fit of the CFA was assessed with model chi-
square, the Comparative Fit Index (CFI), Root Mean 
Square Error of Approximation (RMSEA) and Standard-
ized Root Mean Square Residual (SRMR). Model chi-
square > 0.05, CFI ≥ 0.95, RMSEA < 0.05 and SRMR < 0.05 
indicate a good fit, and CFI > 0.90 and both RMSEA and 
SRMR > 0.05 but < 0.08 indicate an acceptable fit [15, 17]. 
Internal consistency was assessed with Cronbach’s α. A 
Cronbach’s α of 0.70 or higher was considered adequate 
for group level comparisons. Test–retest reliability was 
assessed based on the questionnaires administered at 
T12mo and T12mo + 2wk using the intraclass correla-
tion coefficient for absolute agreement (ICC; two-way 
mixed model, single measure) [18]. An ICC value of 0.70 
or higher was considered acceptable.
Divergent validity of the QLQ-NMIBC24 was assessed 
by calculating the Spearman correlation coefficients 
between the scales of the QLQ-C30 and QLQ-NMIBC24 
[19]. Based on previous studies, we expected in general 
low to moderate correlations (< 0.40) between the scales 
of both questionnaires. Previous studies have shown that 
malaise was moderately to strongly correlated (> 0.40) 
with all the scales of the QLQ-C30 [2, 6, 16]. The urinary 
symptom scale has previously also shown to be moder-
ately (0.40–0.69) correlated with role function, cognitive 
function, social function, fatigue, nausea and vomiting, 
and pain [2, 6]. At last, future worries was expected to be 
moderately correlated to the emotional function scale of 
the QLQ-C30 [2] and fatigue [6].
Known group validity was assessed by comparing 
patients with low, intermediate and high risk NMIBC 
using independent t-tests. Patients were divided into 
risk groups based on the European Association of Urol-
ogy (EAU) guidelines [1] without taking into account 
the tumour size (not available) and the recurrent nature 
of the tumour (only primary tumours included). We 
hypothesized that patients with high risk NMIBC would 
have more urinary symptoms, malaise, future worries 
and intravesical treatment issues at T6wk than patients 
with low risk NMIBC.
Responsiveness to change was examined using all three 
questionnaires of the UroLife study (i.e. T6w, T3mo 
and T15mo) using paired t-tests. We hypothesized that 
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differences on the scales of the NMIBC24 would only be 
small between T6wk and T3mo, but that symptoms and 
complaints decrease from T6wk to T15mo. Effect sizes 
(ESs) were calculated using Cohen’s d statistic (mean 
difference divided by pooled standard deviation). These 
provide a distribution-based estimate of the magnitude 
of mean differences/changes, where an ES of 0.2 is con-
sidered small, 0.5 moderate, and 0.8 large [20].
MIC was assessed using the visual-anchor distribution 
method of De Vet et al. [13]. This method determines the 
smallest change in scores of the QLQ-NMIBC24 that 
are regarded as either improvement or deterioration by 
taking into account the variability and importance of 
the scores. To determine the importance of the scores, 
an external anchor is used. Correlations between the 
anchor-question and the scales of the QLQ-NMIBC24 
were assessed to determine the adequacy of the anchor 
(r ≥ 0.40) (i.e. does the anchor question measures the 
same as the change scores?). Then, patients were subdi-
vided into three groups (importantly deteriorated, not 
importantly changed and importantly improved) using 
the anchor question and for each group the distribution 
of the changes scores was plotted. The optimal receiver 
operating curve (ROC) was considered to be the MIC 
value.
The CFA was conducted with the software package R 
using the “lavaan” package [21]. ICCs were calculated in 
STATA version 16.0 (StataCorp LLC, College Station, 
Texas, USA) and SEMs were calculated in SAS (SAS 
Institute, Cary, North Carolina, USA). All other statistical 
analyses were executed using SPSS version 25 (IBM Cor-
poration, Armonk, New York, USA). P values < 0.05 were 
considered statistically significant.
Results
Patient characteristics and data quality
Fifty percent of the NMIBC patients invited for UroLife 
and 58% of the NMIBC patients invited for BlaZIB com-
pleted the baseline questionnaire, resulting in a total 
number of 1463 eligible patients for this study (Fig.  1). 
Figure  1 presents the number of completed question-
naires and the response rates at follow-up. The major-
ity of the patients were male (81%) (Table  1). Patients 
participating in UroLife were, on average, younger (66 
vs. 72  years), more often female (21% vs. 17%), living 
together with a partner (85% vs. 77%) and employed (42% 
vs. 24%) than those participating in BlaZIB.
The percentage of missing responses was low (< 1%) for 
all non-sex related scales at all measurement moments of 
the UroLife study (Table 2). For the sex-related scales, the 
percentage of missing responses varied between 6.9 and 
12.8%, with exception of female sexual problems (41.4–
50.0% missing responses).
At T6wk, only four of the eleven scales had no floor 
effect (< 15%) (Table  2). The highest floor effects were 
observed for malaise (87.1%) and intravesical treatment 
issues (74.5%). Over time, the percentage of patients 
with the lowest possible scores decreased for sexual 
functioning and male sexual problems but remained 
stable or increased for all other scales. At T15mo, floor 
effects were present for all scales. No ceiling effects were 
observed at any assessment point. The percentage of 
missing responses was low for all scales, except for female 
sexual problems (45.7%) (Table 2).
Structural validity
Table 3 shows the results of the multitrait scaling analysis. 
All items had a within-scale correlation of 0.40 or higher 
and a correlation of 0.40 or lower with other scales, indi-
cating good convergent and discriminant validity, respec-
tively. The model chi-square significance was < 0.0001, 
CFI was 0.93, RMSEA was 0.06 and SRMR was 0.04 after 
excluding female sexual function (question answered by 
N = 21), indicating an acceptable fit. Standardized factor 
loadings are presented in Table 4.
Reliability
Internal consistency of the scales at all time points was 
adequate (Cronbach’s α > 0.70), with the exception of 
bloating and flatulence (Cronbach’s α 0.51–0.59) and 
malaise (Cronbach’s α 0.62–0.67) (Table  3). Test–retest 
reliability was acceptable for six scales (ICC > 0.70) and 
fair to moderate for three scales (0.38–0.65) (Table  5). 
Test–retest reliability was the lowest for malaise (0.07).
Construct validity
Correlations between the core questionnaire and the 
NMIBC-module were low (< 0.40) for nearly all scales 
(Table 6). Only between emotional function (QLQ-C30) 
and future worries (QLQ-NMIBC24) a moderate, inverse 
correlation was observed (− 0.57). This indicates that the 
content of the core questionnaire and the NMIBC-spe-
cific module do not overlap excessively.
Comparison of patients’ scores at T6wk according 
to their NMIBC risk subgroups indicated that patients 
with high-risk NMIBC reported more urinary symptoms 
(ES = 0.41), future worries (ES = 0.51), problems with 
sexual intimacy (ES = 0.41) and risk of contaminating 
partner (ES = 0.72) than patients with low-risk NMIBC 
(Table 7).
Responsiveness
At T15mo, all QLQ NMIBC24 scores improved com-
pared to T6wk, except for malaise, bloating and flatu-
lence, and male sexual problems (ES < 0.2) (Table 8).
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Interpretability
Based on the correlations between the anchor question 
and the scales of the questionnaire (ranging between 
− 0.11 and 0.28), the anchor question was deemed 
inadequate and no MIC values were calculated.
Discussion
When evaluating the psychometric properties of the 
EORTC-QLQ-NMIBC24 in Dutch patients with NMIBC, 
we observed good structural validity, reliability (i.e. inter-
nal consistency and test–retest reliability), construct 
validity (i.e. divergent validity and known groups validity) 
Table 1 Sociodemographic characteristics of the NMIBC patients
BCG Bacillus Calmette-Guérin
a  Based on an adapted version of the Self-administered Comorbidity Questionnaire [22], including 14 diseases (cardiovascular disease, stroke, high blood pressure, 











n (%) N (%) N (%) N (%) N (%) N (%) N (%)
Patient characteristics
Age (years), mean (SD) 70 (10) 72 (10) 66 (9) 65 (10) 66 (9) 67 (7)
Gender (% male) 1187 (81%) 761 (83%) 426 (79%) 68 (69%) 196 (78%) 162 (84%)
Living situation
 With partner 1165 (80%) 707 (77%) 458 (85%) 79 (80%) 212 (85%) 167 (87%)
 Without partner 298 (20%) 215 (23%) 83 (15%) 20 (20%) 38 (15%) 25 (13%)
Employment
 Paid job 349 (24%) 171 (19%) 175 (32%) 31 (31%) 89 (36%) 55 (29%)
 No paid job 104 (7%) 49 (5%) 55 (10%) 13 (13%) 25 (10%) 17 (9%)
 Retired 1010 (69%) 699 (76%) 311 (58%) 55 (56%) 136 (54%) 120 (62%)
Comorbiditya
 0 299 (20%) 212 (23%) 87 (16%) 12 (12%) 41 (16%) 34 (18%)
 1 406 (28%) 270 (29%) 136 (25%) 27 (27%) 57 (23%) 52 (27%)
 ≥ 2 739 (51%) 425 (46%) 314 (58%) 59 (60%) 152 (61%) 103 (54%)
 Missing 15 (1%) 15 (2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Smoking status (at baseline)
 Never 225 (15%) 137 (15%) 88 (16%) 19 (19%) 40 (16%) 29 (15%)
 Former 983 (67%) 633 (69%) 350 (65%) 63 (64%) 155 (62%) 132 (69%)
 Current 252 (17%) 149 (16%) 103 (19%) 17 (17%) 55 (22%) 31 (16%)
 Missing 3 (0%) 3 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Tumour characteristics
Tumour stage
 Ta 403 (28%) 0 (0%) 403 (75%) 99 (100%) 250 (100%) 54 (28%)
 T1 907 (62%) 786 (85%) 121 (22%) 0 (0%) 0 (0%) 121 (63%)
 Tis 153 (10%) 136 (15%) 17 (3%) 0 (0%) 0 (0%) 17 (9%)
Tumour grade
 1 156 (11%) 24 (3%) 132 (24%) 99 (100%) 29 (12%) 4 (2%)
 2 385 (26%) 125 (14%) 260 (48%) 0 (0%) 221 (88%) 39 (22%)
 3 894 (61%) 747 (81%) 147 (57%) 0 (0%) 0 (0%) 147 (77%)
 Missing 28 (2%) 26 (3%) 2 (0%) 0 (0%) 0 (0%) 2 (1%)
Adjuvant intravesical therapy
 None 447 (31%) 176 (19%) 271 (50%) 91 (92%) 157 (63%) 23 (12%)
 Chemotherapy 146 (10%) 17 (2%) 129 (24%) 7 (7%) 82 (33%) 40 (21%)
 BCG 808 (55%) 690 (75%) 118 (22%) 1 (1%) 7 (3%) 110 (57%)
 BCG + Chemotherapy 62 (4%) 39 (4%) 23 (4%) 0 (0%) 4 (2%) 19 (10%)
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and responsiveness. The number of missing items were 
low among patients for whom the items were applicable, 
with exception of female sexual problems. At all meas-
urement points, multiple floor effects were observed and 
MIC values could not be determined.
Multitrait scaling analysis and Cronbach’s α for inter-
nal consistency supported the scale structure of the 
QLQ-NMIBC24. Only the bloating and flatulence and 
malaise scales (at follow-up) did not reach the 0.70 cut 
off for group level use of the items in these scales. Other 
authors have reported similar results and also found that 
the bloating and flatulence [2] and especially the malaise 
scale [2, 5, 6] seems to yield unsatisfactory results. These 
results suggest that there is heterogeneity of the two 
items in the malaise scale, i.e. items cannot be grouped 
into one scale, and a revision of this scale may be needed.
The high number of scales with floor effects we 
observed at T6wk has also been found by other stud-
ies. Park et  al. observed floor effects in nine scales and 
Mogensen et  al. found floor effects in 20 out of the 24 
items of the questionnaire [5, 6]. Malaise, intravesi-
cal treatment issues and bloating and flatulence had 
the highest percentages of lowest possible scores in all 
studies (range 43.3% up to 90%) [2, 5, 6]. Floor effects at 
Table 2 Missing responses, floor effects and ceiling effects of scales of the EORTC QLQ-NMIBC24 for 541 NMIBC patients participating 
in UroLife
a For 426 (T6wk)/368 (T3mo)/328 (T15mo) men
b For 502 (T6wk)/451 (T3mo)/402 (T15mo) men and women indicating this item was applicable to them
c For 234 (T6wk)/231 (T3mo)/219 (T15mo) men and women indicating to be sexually active
d For 35 (T6wk)/30 (T3mo)/29 (T15mo) women indicating to be sexually active
Scale T6wk (n = 541) T3mo (n = 471) T15mo (n = 423)
% Missing % Floor % Ceiling % Missing % Floor % Ceiling % Missing % Floor % Ceiling
Scales
Urinary symptoms 0.2 9.6 0 0.4 10.4 0 0.7 17.7 0
Malaise 0 87.1 0.6 0.2 86.8 0.2 0.7 90.8 0.2
Future worries 0.2 14.4 1.8 0.2 18.3 0.8 0.2 24.6 0.5
Bloating and flatulence 0 46.0 0.6 0.2 43.3 0.6 0.2 48.0 0.2
Sexual functioning 7.8 37.3 0.6 7.4 32.3 0.4 10.6 28.4 0.5
Male sexual  problemsa 10.3 38.3 7.5 12.8 37.2 5.7 12.8 30.5 8.2
Single items
Intravesical treatment  issuesb 0.6 74.5 0.4 0.7 76.1 0.7 0.5 84.1 0.5
Sexual  intimacyc 7.3 62.8 0.9 6.9 70.1 1.3 7.4 70.5 0.5
Risk of contaminating partner 7.7 52.6 3.4 7.8 61.0 1.3 7.4 71.1 2.1
Sexual enjoyment 9.0 17.5 3.8 9.1 14.3 3.0 8.4 20.5 3.2
Female sexual  problemsd 45.7 14.3 0 50.0 36.7 6.7 41.4 44.8 0
Table 3 Item convergent and discriminant correlations by scale within the EORTC QLQ-NMIBC24 at each follow-up time point for 541 
NMIBC patients participating in UroLife (multitrait scaling analysis and internal consistency)
Con convergent validity, dis discriminant validity
a Range of item-scale correlations corrected for overlap
b Range of correlations between an item and all other scales
c Cronbach’s alpha
Scale T6wk (n = 541) T3mo (n = 471) T15mo (n = 423)
Cona Disb αc Cona Disb α c Con a Disb α c
Urinary symptoms 0.53–0.82 − 0.21 to 0.26 0.85 0.51–0.82 − 0.18 to 0.31 0.86 0.45–0.84 − 0.11 to 0.27 0.82
Malaise 0.57–0.97 − 0.02 to 0.26 0.72 0.61–0.97 − 0.15 to 0.29 0.67 0.61–0.98 − 0.05 to 0.20 0.62
Future worries 0.82–0.89 − 0.06 to 0.25 0.90 0.83–0.87 − 0.07 to 0.26 0.89 0.83–0.88 0.00–0.26 0.90
Bloating and flatulence 0.74–0.89 − 0.07 to 0.22 0.59 0.71–0.89 − 0.05 to 0.27 0.57 0.66–0.90 − 0.13 to 0.23 0.51
Sexual functioning 0.91–0.94 − 0.21 to (− 0.02) 0.83 0.92–0.95 − 0.28 to (− 0.05) 0.86 0.91–0.95 − 0.19 to (− 0.04) 0.85
Male sexual problems 0.83–0.92 − 0.21 to 0.25 0.77 0.88–0.91 − 0.28 to 0.31 0.77 0.85–0.91 − 0.19 to 0.27 0.74
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baseline may impose a problem as further decreases in 
symptoms and function over time, as is the case in our 
study, cannot be measured. Reviewing the relevance of 
scales with high floor effects at baseline might improve 
the usefulness of this questionnaire.
The low correlations between the scales of the QLQ-
C30 and the QLQ-NMIBC24 questionnaires indicate 
good discriminant validity and added value of the QLQ-
NMIBC24 to the core questionnaire. We could not con-
firm the moderate correlation (> 0.40) between malaise 
and urinary symptoms of the QLQ-NMIBC24 and the 
scales of the QLQ-C30 as observed in previous studies, 
but did confirm the moderate correlation between future 
worries and emotional function [2, 6].
We found that the QLQ-NMIBC24 is able to discrimi-
nate between subgroups (i.e., NMIBC risk profile) and 
to measure change over time. However, the difference 
found for malaise by NMIBC risk profile was small and 
non-significant. Other studies have found significant dif-
ferences in most scales according to physical function 
(> 90 vs < 90) [2] and Karnofsky performance status [6]. 
For gender comparisons, only differences in sexual func-
tion and sexual enjoyment were observed [2;6]. All stud-
ies were able to detect changes in score over time [2, 6].
For the test–retest reliability and interpretability, we 
used an anchor-question and measurement scale to 
determine changes in patient’s health over the course of 
time in line with previous recommendations [12]. How-
ever, it might not be suitable to assess changes in malaise 
(ICC of 0.07) as other, non-bladder cancer related, health 
issues may affect malaise as well. Furthermore, both 
malaise, as a consequence of treatment, and intravesi-
cal treatment issues are highly dependent on the tim-
ing of the questionnaire in the treatment process, which 
might also explain the rather low test–retest reliability 
for these scales. In addition, we were not able to calculate 
Table 4 Standardised factor loadings for the EORTC QLQ-NMIBC24 for 541 NMIBC patients participating in UroLife (confirmatory 
factor analysis)
a This scale was excluded from the confirmatory factor analysis
b All p values were < 0.0001
Scales and items Item # Item topic Standardized 
factor  loadingsb
Urinary symptom Item 31 Have you had to urinate frequently during the day? 0.682
Item 32 Have you had to urinate frequently at night? 0.622
Item 33 When you felt the urge to pass urine, did you have to hurry to get to the toilet? 0.768
Item 34 Was it difficult for you to get enough sleep, because you needed to get up frequently at 
night to urinate?
0.593
Item 35 Have you had difficulty going out of the house, because you needed to be close to a 
toilet?
0.586
Item 36 Have you had any unintentional release (leakage) of urine? 0.334
Item 37 Have you had pain or a burning feeling when urinating? 0.497
Malaise Item 38 Did you have a fever? 0.159
Item 39 Did you feel ill or unwell? 0.591
Future worries Item 41 Did you worry about having repeated bladder treatments (cystoscopies or instillations)? 0.618
Item 42 Were you worried about your health in the future? 0.692
Item 43 Did you worry about the results of examinations and tests? 0.700
Item 44 Did you worry about possible future treatments? 0.736
Bloating and flatulence Item 45 Did you have a bloated feeling in your abdomen? 0.696
Item 46 Have you had flatulence or gas? 0.339
Sexual functioning Item 47 To what extent were you interested in sex? 0.700
Item 48 To what extent were you sexually active (with or without sexual intercourse)? 0.542
Male sexual problems Item 49 For men only: Dit you have difficulty gaining or maintaining an erection? 0.870
Item 50 For men only: Did you have ejaculation problems (e.g. dry ejaculation)? 0.827
Intravesical treatment issues Item 40 Did you have trouble arranging your life around the repeated bladder treatment appoint-
ments (cystoscopies or instillations)?
0.564
Sexual intimacy Item 51 Have you felt uncomfortable about being sexually intimate? 0.690
Risk of contaminating partner Item 52 Have you worried that you may contaminate your partner during sexual contact with the 
bladder treatment you have been receiving?
0.821
Sexual enjoyment Item 53 To what extent was sex enjoyable for you? 0.941
Female sexual  problemsa Item 54 For women only: did you have a dry vagina or other problems during intercourse?
Page 9 of 12Ripping et al. J Patient Rep Outcomes            (2021) 5:96  
MIC values as the correlations between the scores on the 
anchor-question and change scores were too low. Other 
factors, such as the different modes of administration in 
the test–retest analysis (online vs. paper), may have also 
contributed to these findings. Future research will be 
necessary to determine MIC values for the NMIBC24.
A limitation of this study is the response rate for both 
questionnaires, i.e. 50% and 58% for UroLife and BlaZIB, 
respectively. Although our response rates are as expected 
for Dutch patients with NMIBC, selective non-response 
may affect the generalizability of the scores to the entire 
Dutch patient population with NMIBC. We do, how-
ever, not expect selective non-response as participants 
of the UroLife study were comparable with respect to 
age, gender and tumour stage to the non-responders 
(data not shown). Furthermore, selective loss to follow-
up might have affected some of our results concerning 
comparison of outcomes over time (i.e. responsiveness), 
although analyses based on patients who participated 
in all three UroLife questionnaires (T6wk, T6mo and 
T15mo) showed similar results (data not shown). At 
last, the sparse number of sexual active women in our 
study (n = 35 at T6wk; n = 0 test–retest analysis) limited 
the examination of the item female sexual problems; we 
omitted this item from the CFA and could not assess the 
ICC. Previous studies investigating the psychometric 
properties of the QLQ-NMIBC24 have also dealt with a 
low number of female sexual active participants [2, 5, 6] 
Table 5 Intraclass correlation coefficient of the QLQ-NMIBC24 subscales for 134 NMIBC patients participating in the test–retest 
analysis of BlaZIB
ICC, intraclass correlation coefficient, CI confidence interval, SEM standard error of measure
a Using the Restricted Maximum Likelihood (REML) approach
b Patients who (self-reported) remained the same with respect to the specific assessment of stability (i.e. urinary, bowel, sexual or total function) between the T12mo 
and T12mo + 2wk questionnaire
Scale Assessment of stability Number of stable 
 patientsb
ICC (95% CI) SEMa
Urinary symptoms Urinary function 80 0.70 (0.57–0.80) 10.0
Malaise Total function 78 0.07 (− 0.15 to 0.29) 12.9
Future worries Total function 60 0.78 (0.66–0.86) 8.4
Bloating and flatulence Bowel function 56 0.65 (0.46–0.78) 12.4
Sexual functioning Sexual function 58 0.82 (0.72–0.89) 8.9
Male sexual problems Sexual function 49 0.74 (0.57–0.84) 18.3
Intravesical treatment issues Total function 76 0.38 (0.17–0.56) 11.8
Sexual intimacy Sexual function 22 0.73 (0.46–0.88) 11.4
Risk of contaminating partner Sexual function 20 0.40 (− 0.04 to 0.71) 15.2
Sexual enjoyment Sexual function 20 0.71 (0.40–0.87) 14.9
Female sexual problems Sexual function 0
Table 6 Spearman correlations between scales in the QLQ-C30 and QLQ-NMIBC24 for 541 NMIBC patients participating in UroLife 
(divergent validity)
a The signs (–) and (+) indicate whether higher scores on this scale are worse or better, respectively
QLQ-C30 scales QLQ-NMIBC24 scales
Urinary 
symptoms (–)a








Physical function (+)a − 0.23 − 0.16 − 0.11 − 0.13 0.24 − 0.18
Role function (+)a − 0.33 − 0.27 − 0.22 − 0.23 0.14 − 0.14
Emotional function (+)a − 0.25 − 0.24 − 0.57 − 0.26 0.10 − 0.12
Cognitive function (+)a − 0.15 − 0.20 − 0.21 − 0.24 0.07 − 0.17
Social function (+)a − 0.31 − 0.26 − 0.32 − 0.25 0.12 − 0.14
Global Quality of Life (+)a − 0.38 − 0.33 − 0.37 − 0.25 0.16 − 0.16
Pain (–)a 0.35 0.27 0.31 0.25 − 0.13 0.15
Fatigue (–)a 0.26 0.28 0.27 0.26 − 0.15 0.12
Nausea and vomiting (–)a 0.14 0.36 0.10 0.17 − 0.03 0.03
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and often lower than is considered adequate according to 
the COSMIN study design checklist for patient-reported 
outcome measures [7]. As a  consequence, it is hard to 
draw solid conclusions about the single item female sex-
ual problems.
Conclusions
The QLQ-NMIBC24 questionnaire has in general a 
good structural validity, reliability, construct validity and 
responsiveness. The reliability of the scales malaise and 
bloating and flatulence is, however, suboptimal. Relevant 
change scores for this questionnaire could not be defined 
Table 7 Mean scores (± SD) of EORTC QLQ-NMIBC24 subscales at 6 weeks after diagnosis for 541 NMIBC patients participating in 
UroLife by risk category (known group validity)
a Effect size of 0.2 is considered small, 0.5 moderate, and 0.8 large
b p ≤ 0.05
c p ≤ 0.001
d The signs (–) and (+) indicate whether higher scores on this scale are worse or better, respectively
Patient score, mean (SD) Effect  sizea
Low risk (N = 99) Intermediate risk 
(N = 250)
High risk (N = 192) Intermediate vs. 
low
High vs. low
Urinary symptoms (–)d 24.5 (20.8) 26.3 (20.1) 33.1 (21.3) 0.09 0.41c
Malaise (–)d 2.4 (10.8) 3.7 (13.7) 4.3 (10.4) 0.11 0.18
Future worries (–)d 28.4 (20.8) 30.6 (24.1) 40.1 (24.5) 0.10 0.51c
Bloating and flatulence (–)d 21.6 (23.2) 15.4 (20.5) 17.8 (20.8) − 0.28b − 0.17
Sexual functioning (+)d 23.3 (22.3) 21.5 (22.9) 21.7 (22.4) − 0.08 − 0.07
Male sexual problems (–)d 30.9 (30.1) 26.5 (33.1) 29.1 (33.1) − 0.14 − 0.07
Intravesical treatment issues (–)d 9.9 (17.6) 8.0 (17.9) 12.7 (20.4) − 0.11 0.15
Sexual intimacy (–)d 9.2 (19.3) 12.1 (21.7) 18.2 (24.2) 0.14 0.41b
Risk of contaminating partner (–)d 9.7 (21.7) 15.5 (22.8) 29.1 (31.3) 0.26 0.72c
Sexual enjoyment (+)d 47.2 (28.2) 44.3 (29.3) 44.4 (31.2) − 0.10 − 0.09
Female sexual problems (–)d 37.5 (33.0) 33.3 (19.2) 27.8 (25.1) − 0.16 0.33
Table 8 Unadjusted mean scores (± SD) of EORTC QLQ-NMIBC24 subscales for 541 NMIBC patients participating in UroLife at three 
time points after diagnosis and mean differences at 3 months (T3mo) and 15 months (T15mo) compared to 6 weeks (T6wk) after 
diagnosis (responsiveness)
a Effect size was calculated using Cohen’s d statistic (mean difference divided by pooled standard deviation) and 0.2 is considered small, 0.5 moderate, and 0.8 large
b p ≤ 0.05
c p ≤ 0.01
d p ≤ 0.001
e The signs (–) and (+) indicate whether higher scores on this scale are worse or better, respectively
Patient score, mean (SD) Effect  sizea
T6wk (N = 541) T3mo (N = 471) T15mo (N = 423) T3mo vs. T6wk T15mo vs. T6wk
Urinary symptoms (–)e 28.4 (21.0) 22.3 (19.3) 17.8 (16.4) − 0.27d − 0.53d
Malaise (–)e 3.7 (12.1) 3.4 (10.5) 2.5 (9.5) − 0.02 − 0.08
Future worries (–)e 33.6 (24.1) 29.5 (22.6) 24.7 (21.4) − 0.17d − 0.38d
Bloating and flatulence (–)e 17.4 (21.2) 17.1 (20.4) 14.4 (18.0) 0.00 − 0.14c
Sexual functioning (+)e 21.9 (22.6) 24.4 (22.2) 27.1 (23.2) 0.09d 0.23d
Male sexual problems (–)e 28.1 (32.6) 27.5 (31.2) 33.3 (33.0) − 0.01 0.12b
Intravesical treatment issues (–)e 10.0 (18.8) 9.5 (18.7) 6.2 (15.7) 0.02 − 0.23d
Sexual intimacy (–)e 13.8 (22.4) 10.4 (20.0) 10.1 (19.2) − 0.20c − 0.29c
Risk of contaminating partner (–)e 19.3 (27.0) 14.3 (22.7) 10.0 (21.5) − 0.20b − 0.46d
Sexual enjoyment (+)e 45.0 (29.7) 42.9 (26.5) 41.9 (29.1) − 0.12 − 0.20b
Female sexual problems (–)e 33.3 (25.8) 18.8 (36.5) 12.7 (24.7) − 0.34 − 1.16b
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due to the low correlation between our anchor question 
and change scores.
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